Gerresheimer's €1.5bn Divestment Poses a Stark Question: Is the Company Now Worth Less Than What It Just Sold?

Gerresheimer's €1.5B divestment exceeds its market cap, yet shares stay flat amid accounting woes and GLP-1 slowdown.

The arithmetic is jarring. Gerresheimer has agreed to offload two business units for roughly €1.5 billion, yet the entire company carries a market capitalisation of just €917 million. That disconnect — a conglomerate valued below the cash it is pulling in from disposals — captures the depth of investor scepticism surrounding the German pharma packaging group.

The deal, completed on 29 July, sees US subsidiary Centor and the global Primary Packaging Plastics (PPP) division pass to private equity firm Apax Partners. The proceeds are earmarked to tackle a debt burden that ballooned following an internal probe into so-called "bill-and-hold" transactions — a practice where revenue is booked while goods remain in the seller's warehouse. That accounting issue delayed the 2025 annual report for months before figures finally landed in late June, showing revenue of €2.321 billion including the acquired Bormioli Pharma, alongside adjusted EBITDA of €384.0 million.

A Market That Refuses to Celebrate

The share price response has been muted at best. Gerresheimer stock trades at €26.72, up a modest 0.60 percent on the day — hardly the reaction one might expect from a deleveraging event of this magnitude. The market's reluctance to embrace the deal stems partly from what the divestment reveals about the company's trajectory: Gerresheimer is now a smaller, more concentrated business, having surrendered a substantial revenue-generating arm.

The 12-month picture is grim, with the stock down 41 percent. The once-celebrated growth narrative — Gerresheimer was long viewed as a prime beneficiary of the GLP-1 weight-loss drug boom, supplying packaging to pharma giants such as Novo Nordisk — has faded as disappointing trial data and cautious forecasts from major drugmakers ripple through the supply chain.

Two Analyst Camps, Two Divergent Views

The sell-side is split on what the disposal means for shareholders. Bernstein Research reaffirmed a price target of €28.70 on 29 July, suggesting the deal carries strategic merit. Jefferies, also weighing in on the same day, took a more circumspect stance with a "Hold" rating and a €26.80 target, arguing the market had already priced in the transaction.

Institutional investors have shown some conviction: back in May, AOC Gecko and the Active Ownership Fund acquired shares worth over €10 million at prices around €28.30. That vote of confidence, however, predates the full realisation of the current uncertainty.

Technical Signals Point Both Ways

Chart analysis offers a similarly mixed read. The stock sits 1.28 percent below its 50-day moving average of €27.07, indicating that the immediate post-deal momentum has yet to convince. Yet it also trades 8.87 percent above its 200-day average of €24.54, suggesting the worst of the sell-off — which bottomed at a yearly low in February — may be behind it. The secondary source puts the stock at €26.56, roughly 8 percent above that longer-term benchmark, though it notes a further 9 percent decline over the past 30 days.

Volatility tells its own story: annualised volatility stands above 43 percent, with one assessment placing it near 46 percent. That elevated figure reflects a market still pricing in considerable uncertainty about what comes next.

The Path to Credibility

The central question is not whether the €1.5 billion will be received, but whether it will meaningfully reduce net debt without being eroded by operational demands from the remaining core — injection systems, vials and medical devices. Management must demonstrate in upcoming quarterly reports that the deleveraging is genuine and that the slimmed-down group can still grow profitably.

There are encouraging signs on the operational front. Late July saw the commissioning of a new primary packaging plant in Zhenjiang Dagang, China, signalling continued investment in the surviving business lines despite the crisis. But the overhang from the bill-and-hold investigation persists: until it is clear that no further accounting skeletons will emerge, trust remains fragile.

Two upcoming dates will test the narrative. The ordinary virtual annual general meeting is scheduled for 1 September, followed by the half-year financial report for 2026, expected in September or October. Those events will reveal whether the Centor disposal marks a genuine inflection point or merely a pause in a crisis that has yet to fully play out. For now, the market's verdict is clear: a company worth less than the assets it just sold has much to prove.